Here are the 424B prospectus supplements from MapLight Therapeutics, Inc. (MPLT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.
MapLight Therapeutics, Inc. (MPLT) registered up to 13,181,055 shares of voting common stock for resale by selling stockholders: 9,197,887 issued shares and 3,983,168 shares issuable upon exercise of outstanding pre-funded warrants. Upon effectiveness, the shares may be sold in the open market; selling stockholders may sell all, some or none.
MapLight is not selling shares and will receive no proceeds from stockholder resales. It will receive the $0.0001-per-share exercise price if pre-funded warrants are exercised for cash. The shares originated in a private placement that closed August 14, 2026, from which MapLight received approximately $150.0 million in gross proceeds before placement agent fees and estimated offering expenses.
The company describes Phase 2 development of lead candidate ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis. Topline results from its VISTA Alzheimer’s disease psychosis trial are expected in the second half of 2027.